新型冠状病毒肺炎与血栓：从基础到临床。
COVID-19 and thrombosis: From bench to bedside.
机构信息
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York- Binghamton, NY, USA.
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, State University of New York- Binghamton, NY, USA.
出版信息
Trends Cardiovasc Med. 2021 Apr;31(3):143-160. doi: 10.1016/j.tcm.2020.12.004. Epub 2020 Dec 16.
Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19.
2019 年冠状病毒病（COVID-19）是由冠状病毒 SARS-CoV2（严重急性呼吸系统综合症冠状病毒 2）引起的呼吸道病毒感染。尽管 COVID-19 是一种呼吸道疾病，但已发现它会增加静脉和动脉血栓栓塞事件的风险。实际上，COVID-19 与血栓之间的联系引起了广大科学界的关注。在这篇综述中，我们将分析目前关于 COVID-19 和血栓形成之间关联的现有知识。我们将重点介绍可能解释这种关联的分子和细胞水平上的机制。此外，本文还将回顾目前在 COVID-19 管理中使用或正在研究的抗血栓药物的抗血栓特性。最后，我们将讨论当前专业协会关于 COVID-19 相关血栓栓塞预防和治疗的指南。
Zotero 插件